Carma Laboratories brings pizzazz to lip care with Carmex Moisture Plus limited-edition designs
MILWAUKEE — Carma Laboratories on Tuesday launched Carmex Moisture Plus limited-edition designs, a slim-stick lip balm line that presents a fashion-forward exterior. The line features limited-edition designs and named personalities to match, including Chic in houndstooth, Fab in a groovy retro look, Adventurous in a leopard print and Whimsical in an art deco design.
The brand is asking consumers, “Which personality are you?”
“Lip care is an important component of a daily beauty regimen, and consumers need a product they can rely on that protects and serves as an important foundation,” stated Paul Woelbing, president of Carma Laboratories. “The goal of the new Carmex Moisture Plus line is to offer our consumers a hard-working lip balm line that represents and reflects their unique style.”
New designs will be introduced to reflect upcoming fashion trends and give consumers a unique way to flaunt their personal style. The first styles in the new line will begin to hit store shelves in late-summer 2013 at CVS, Dollar General, Walgreens, Walmart and other stores across the U.S. Suggested retail price is $2.99.
Mixing track-and-trace, compounding: Would bill unfairly burden pharmacies?
Big data finds another application and another supporter. Sort of.
The full Senate will shortly take up a new track-and-trace bill (S. 959), which would establish a national system for tracking the pedigree and movement of most pharmaceuticals, from point of manufacture and distribution to the dispensing pharmacy and the patient at the end of the supply chain. The goal: to replace the hodge-podge of different state laws with a single, nationwide track-and-trace system capable of capturing the daily flood of drug production, distribution, dispensing and utilization data and channeling it into an accessible tool by which stakeholders and regulators could secure the pharmaceutical supply chain.
All well and good, says the National Community Pharmacists Association, the biggest lobbying group for independent pharmacy. But the NCPA is unhappy with a provision of S. 959 that would significantly beef up federal oversight of pharmacy-based drug compounding in the wake of a deadly outbreak of fungal meningitis last year whose source was traced to the New England Compounding Center.
In a statement July 25, NCPA CEO Doug Hoey praised Congress’ new effort to secure the drug supply network. But Hoey also expressed “serious concerns” with the legislation. The bill, he said, “would grant FDA unrestricted authority to establish a list of ‘do not compound’ medications which, based on FDA interpretation, could impact patient access to compounded drugs.
“Community pharmacies already struggle with growing regulatory mandates, yet the legislation would also require pharmacies to notify FDA, rather than their state board of pharmacy, when compounding medications already recognized by FDA as being in short supply,” Hoey added. Hoey suggests that lawmakers split the proposed bill in two, separating the track-and-trace legislation from a new, more carefully considered effort to address the meningitis outbreak and compounding safety.
Are NCPA’s reservations justified? Do the additional FDA reporting requirements for drug compounding represent a new burden on pharmacies and a new hurdle for patient access to needed medicines? Click on the comment link to share your thoughts.
Salonpas introduces new Deep Relieving Gel
FLORHAM PARK, N.J. — Hisamitsu America, a division of Hisamitsu Pharmaceutical Co. Inc. and the manufacturers of Salonpas, an OTC pain patch that is FDA approved and clinically proven, last week announced the launch of Salonpas Deep Relieving Gel, a topical analgesic solution.
"Transdermal creams, gels, foam and patches offer a unique way of delivering medication to your body, which offers significant advantages over taking medications orally," says Dr. Sylvia Hesse, who is an orthopedic medicine specialist at Manhattan Spine and Sports Medicine." One of the biggest advantages is that the medication is delivered directly to the site of pain. Direct application allows a higher concentration of the drug to reach the tissue that needs it. The total amount of medication absorbed into the bloodstream is low, leading to a very low incidence of side effects in contrast to oral medications. Topical treatments can use less medicine and get the same or better relief."
"While many Americans still turn to over-the-counter pills to relieve pain, topical analgesic pain relief is gaining market recognition and we are proud to bring to market solutions that are well-tested and manufactured to the highest quality," said John Incledon, president and CEO of Hisamitsu America.
Designed to penetrate deep to relieve the toughest muscle and joint pain, Salonpas Deep Relieving Gel is an easy-to-use topical analgesic that starts to deliver pain relief in seconds, the company noted. With three active ingredients, camphor (3.1%), menthol (10%) and methyl salicylate (15%), Deep Relieving Gel rushes strong medicine where you need it in a fast-melting, quick-absorbing, clear, non-greasy formula.
New Salonpas Deep Relieving Gel is available at leading retailers nationwide.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.